Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:36:28 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:SGEN from 2023-04-27 to 2024-04-26 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-12-15 17:00U:SGENNews ReleasePADCEV ‚ ® (enfortumab vedotin-ejfv) with KEYTRUDA ‚ ® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
2023-12-10 19:30U:SGENNews ReleaseADCETRIS ‚ ® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
2023-12-06 08:15U:SGENNews ReleaseTUKYSA ‚ ® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
2023-11-30 17:00U:SGENNews ReleaseFDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV ‚ ® (enfortumab vedotin-ejfv) with KEYTRUDA ‚ ® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2023-11-03 12:00U:SGENNews ReleaseSeagen Highlights First Solid Tumor Data for an ADCETRIS ‚ ® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2023-11-02 13:00U:SGENNews ReleaseNew Data for ADCETRIS ‚ ® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
2023-11-01 08:00U:SGENNews ReleaseSeagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
2023-10-22 10:30U:SGENNews ReleaseTIVDAK ‚ ® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
2023-10-22 10:30U:SGENNews ReleaseGroundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV ‚ ® (enfortumab vedotin-ejfv) and KEYTRUDA ‚ ® (pembrolizumab) in First-Line Advanced Bladder Cancer
2023-10-22 10:30U:SGENNews ReleaseTIVDAK ‚ ® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
2023-10-22 10:30U:SGENNews ReleaseGroundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV ‚ ® (enfortumab vedotin-ejfv) and KEYTRUDA ‚ ® (pembrolizumab) in First-Line Advanced Bladder Cancer
2023-10-16 08:00U:SGENNews ReleaseSeagen to Highlight Overall Survival Data for PADCEV ‚ ® and TIVDAK ‚ ® during Presidential Symposium at ESMO Congress 2023
2023-10-12 08:00U:SGENNews ReleaseSeagen to Report Third Quarter 2023 Financial Results on November 1, 2023
2023-09-22 05:00U:SGENNews ReleasePADCEV ‚ ® (enfortumab vedotin-ejfv) and KEYTRUDA ‚ ® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
2023-09-22 05:00U:SGENNews ReleasePADCEV ‚ ® (enfortumab vedotin-ejfv) and KEYTRUDA ‚ ® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
2023-09-04 15:00U:SGENNews ReleaseSeagen and Genmab Announce TIVDAK ‚ ® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
2023-09-04 15:00U:SGENNews ReleaseGenmab and Seagen Announce That TIVDAK ‚ ® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
2023-08-16 08:00U:SGENNews ReleaseSeagen Phase 3 Trial of TUKYSA ‚ ® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
2023-08-02 08:00U:SGENNews ReleaseSeagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
2023-07-12 08:00U:SGENNews ReleaseSeagen to Report Second Quarter 2023 Financial Results on August 2, 2023
2023-06-20 08:30U:SGENNews ReleasePhase 3 Trial of ADCETRIS ‚ ® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
2023-06-14 20:31U:SGENNews ReleaseSix-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS ‚ ® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
2023-06-13 03:01U:SGENNews ReleaseSeagen Announces ADCETRIS ‚ ® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
2023-05-30 15:22U:SGENNews ReleaseSeagen Stockholders Approve Acquisition by Pfizer
2023-04-27 08:00U:SGENNews ReleaseSeagen Reports First Quarter 2023 Financial Results